New PET scans could unmask hidden tumors in rare hormone disorder

NCT ID NCT02019706

Recruiting now Diagnosis Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 09, 2026 · Updated 3 times

Summary

This study compares advanced PET scans (68Ga-DOTATATE and F-DOPA) with standard imaging to locate hidden tumors causing ectopic Cushing syndrome. About 80 adults with this condition will undergo multiple scans over time. The goal is to see which scan or combination best finds the tumor source, potentially improving diagnosis and treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 68Ga-DOTATATE and 18F-DOPA radioligands
What this could lead to: If successful, this could help doctors find hidden tumors in people with ectopic Cushing syndrome, leading to more targeted treatment.
What could go wrong: This is a Phase 2 study with only 80 participants, so results may not apply to everyone. The imaging techniques may not find all tumors, and radiation exposure is a minor risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACTH are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cushing syndrome ectopic Cushing syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACTH CUSHING'S SYNDROME

Contacts and locations

Locations

National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.